Search for: "AstraZeneca AB"
Results 41 - 60
of 92
Sort by Relevance
|
Sort by Date
8 Sep 2014, 4:55 am
.* The skilled person - more knowledgeable than ever beforeDavid covers the exciting pharma-patent ruling in Teva UK Limited & another v AstraZeneca AB [2014] EWHC 2873 (Pat) by Mr Justice Sales in the Patents Court for England and Wales, which focuses on the concept of Common General Knowledge (CGK). [read post]
4 Sep 2014, 1:00 am
So changing the CGK analysis inevitably changes the test for inventive step.All of this helps explain why the IPKat is so exercised by yesterday’s decision in Teva UK Limited & another v AstraZeneca AB [2014] EWHC 2873 (Pat), decided by Mr Justice Sales in the Patents Court. [read post]
31 Aug 2014, 9:05 pm
AstraZeneca AB v. [read post]
16 Aug 2014, 11:39 pm
AstraZeneca AB v Apotex Pty Ltd [2014] FCAFC 99 (12 August 2014)An expanded panel of five judges of the Federal Court of Australia has held that two patents owned by AstraZeneca relating to the cholesterol-lowering drug marketed as CRESTOR (active ingredient rosuvastatin) are invalid. [read post]
23 Jun 2014, 12:57 pm
Gislaved Gummi AB, 178 F. 3d 257, 263–264 (4th Cir. 1999) (citing cases); Wells v. [read post]
4 May 2014, 3:14 am
Specifically, in AstraZeneca AB v Alphapharm Pty Ltd [2014] FCA 419, the patentee has been awarded a higher level of attorney fees under section 19 of the Patents Act, which relates to Certificates of Validity. [read post]
3 Feb 2014, 7:11 pm
Astrazeneca AB at *5. [read post]
30 Dec 2013, 8:50 pm
Noonan -- A classic example of product "evergreening" is how AstraZeneca used its experience with its omeprazole franchise (sold for over a decade as Prilosec®) to promote an alternative form of the drug, Nexium® (particularly, the S-omeprazole enantiomer) as "the little purple pill." [read post]
8 Dec 2013, 8:02 pm
Astrazeneca AB et al. v. [read post]
5 Dec 2013, 7:21 am
Astrazeneca AB, et al v. [read post]
27 Oct 2013, 9:55 pm
Astrazeneca AB et al. v. [read post]
31 Jul 2013, 4:58 am
Astrazeneca Pharms. [read post]
24 Mar 2013, 8:01 pm
AstraZeneca AB et al. v. [read post]
20 Nov 2012, 7:50 am
* On Thursday 6 December, judgment will be given in Case C‑457/10 P AstraZeneca AB and Astra Zeneca plc v European Commission. [read post]
26 May 2012, 8:41 pm
Apotex Pty Ltd v AstraZeneca AB [2011] FCA 1520 (14 December 2011) Apotex Pty Ltd v AstraZeneca AB (No 2) [2012] FCA 142 (28 February 2012) Watson Pharma Pty Ltd v AstraZeneca AB [2012] FCA 200 (9 March 2012) Apotex Pty Ltd v AstraZeneca AB (No 3) [2012] FCA 265 (23 March 2012) AstraZenenca’s cholesterol drug CRESTOR will remain without generic competition in the Australian market for the foreseeable future, following… [read post]
15 May 2012, 3:12 pm
457/10 P AstraZeneca AB and AstraZeneca plc v European Commission can be read in full here, The IPKat can't help admire the zeal and zest with which AstraZeneca has fought its corner, first on the question of liability and then on the quantum of the fine. [read post]
20 Apr 2012, 10:36 am
Plaintiffs/Appellants AstraZeneca Pharmaceuticals LP, AstraZeneca AB, IPR Pharmaceuticals, Inc., and The Brigham and Women’s Hospital, Inc. [read post]
25 Mar 2012, 9:25 pm
AstraZeneca AB et al v. [read post]
23 Mar 2012, 4:00 am
& Anor [2012] EWHC 716 (Ch) (22 March 2012) Rohl v Bickland Ltd [2012] EWHC 706 (Ch) (22 March 2012) High Court (Patents Court) Teva UK Ltd & Ors v Astrazeneca AB [2012] EWHC 655 (Pat) (22 March 2012) Regeneron Pharmacueticals Inc v Genentech Inc [2012] EWHC 657 (Pat) (22 March 2012) Source: www.bailii.org [read post]
11 Mar 2012, 3:32 pm
Apotex Pty Ltd v AstraZeneca AB (No 2) [2012] FCA 142 (28 February 2012) Watson Pharma Pty Ltd v AstraZeneca AB [2012] FCA 200 (9 March 2012) Interlocutory injunctions – prima facie case – balance of convenience – whether additional evidence provides grounds to vary previous findings At least five Australian pharmaceutical manufacturers are now ready to launch generic versions of cholesterol-lowering drug CRESTOR, while being barred from… [read post]
